**Poster Session 13**

**Perioperative chemotherapy and advanced disease - increasing experience and new aspects**

**Location:** Room Vienna, North Hall (Level 1)

**Chairs:** P. Patel, Birmingham (GB)
C.N. Sternberg, Rome (IT)
J.A. Witjes, Nijmegen (NL)

**Aims and objectives of this session**

This session will highlight new data on systemic perioperative therapy and advanced bladder cancer, including chemotherapy, immunotherapy and prediction of outcome.

Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion. Extended presentations (+) are 3 minutes in length, followed by 3 minutes for discussion.

---

**170**

**Pembrolizumab produces clinically meaningful responses as first-line therapy in cisplatin-ineligible advanced urothelial cancer: Results from subgroup analyses of KEYNOTE-052**

*By:* Powles T.¹, Bellmunt J.², Castellano D.³, O'Donnell P.⁴, Grivas P.⁵, Vuky J.⁶, Plimack E.⁷, Hahn N.⁸, Balar A.⁹, Pang L.¹⁰, Savage M.¹⁰, Perini R.¹⁰, Keefe S.¹⁰, Bajorin D.¹¹, De Wit R.¹²

*Institutes:* ¹Barts Cancer Institute, Queen Mary University of London, Dept. of Experimental Cancer Medicine, London, United Kingdom, ²Dana-Farber Cancer Institute, Dept. of Genitourinary Oncology, Boston, United States of America, ³Hospital Universitario 12 De Octubre, Dept. of Medicine, Madrid, Spain, ⁴The University of Chicago Medical Centre, Dept. of Medicine, Chicago, United States of America, ⁵Cleveland Clinic, Dept. of Hematology and Oncology, Cleveland, United States of America, ⁶Oregon Health & Science University, Dept. of Oncology, Portland, United States of America, ⁷Fox Chase Cancer Center, Dept. of Hematology and Oncology, Philadelphia, United States of America, ⁸Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center, Dept. of Oncology and Urology, Baltimore, United States of America, ⁹Perlmutter Cancer Center, NYU Langone Medical Center, Dept. of Medicine, New York, United States of America, ¹⁰Merck & Co., Inc., Dept. of Clinical Oncology, Kenilworth, United States of America, ¹¹Memorial Sloan Kettering Cancer Center, Dept. of Medical Oncology, New York, United States of America, ¹²Erasmus MC Cancer Institute, Dept. of Urology and Oncology, Rotterdam, The Netherlands

---

**171**

**Updated meta-analysis (MA) of salvage therapy for metastatic urothelial cancer (mUC): Comparing outcomes of immunotherapy (IT) vs. single agent and doublet chemotherapy (CT)**

*By:* Necchi A.¹, Raggi D.¹, Sonpavde G.², Giannatempo P.³, Mariani L.³, Galsky M.³, Bellmunt J.⁴, Miceli R.⁴

*Institutes:* ¹Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ²UAB Comprehensive Cancer Center, Dept. of Medical Oncology & Hematology, Birmingham, United States of America, ³Fondazione IRCCS Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, ⁴Fondazione IRCCS Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, ⁵Mount Sinai School of Medicine, Tisch Cancer Institute, Dept. of Medical Oncology, New York, United States of America, ⁶Dana-Farber Cancer Institute and Harvard Medical School, Dept. of Medical Oncology, Boston, United States of America

---

**172**

**Adjuvant chemotherapy vs. observation following radical cystectomy for pT3-4 and/or pN+ urothelial carcinoma of the bladder previously treated with neoadjuvant chemotherapy**

*By:* Seisen T.¹, Jamzadeh A.², Vetterlein M.¹, Von Landenberg N.¹, Gild P.¹, Menon M.², Rouprêt M.², Sun M.¹, Choueiri T.², Bellmunt J.², Trinh Q.-D.¹

*Institutes:* Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, ²Henry Ford Health
Comparative effectiveness of selective adjuvant versus systematic neoadjuvant chemotherapy-based strategy for muscle-invasive urothelial carcinoma of the bladder
By: Seisen T.1, Sonpavde G.2, Kachroo N.3, Lipsitz S.4, Leow J.5, Menon M.3, Gild P.1, Von Landenberg N.1, Roupert M.5, Kibel A.3, Sun M.5, Pal S.4, Bellmunt J.5, Choueiri T.1, Trinh Q.-D.1
Institutes: Brigham and Women's Hospital, Harvard Medical School, Division of Urological Surgery and Center For Surgery and Public Health, Boston, United States of America, University of Alabama At Birmingham, Division of Hematology-Oncology, Department of Medicine, Birmingham, United States of America, Henry Ford Health System, VUI Center for Outcomes Research, Analytics and Evaluation, Vattikuti Urology Institute, Detroit, United States of America, Brigham and Women's Hospital, Harvard Medical School and Harvard T.H. Chan School of Public Health, Center for Surgery and Public Health, Boston, United States of America, Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy, IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy.

Neoadjuvant sorafenib, gemcitabine, and cisplatin (SGC) for muscle-invasive urothelial bladder cancer (MIUBC): Final results and translational findings of an open-label, single-arm, phase 2 study
By: Necchi A.1, Lo Vullo S.2, Raggi D.1, Giannatempo P.1,1, Nicolai N.2, Piva L.3, Biasoni D.2, Catanzaro M.4,3, Torelli T.3, Stagni S.3, Calareso G.4, Togliardi E.3, Colecchia M.6, Busico A.6, Perrone F.6, Pennati M.1, Zaffaroni N.1, Mariani L.1, Salvioni R.3
Institutes: Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Medical Oncology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Clinical Epidemiology and Trials Organization Unit, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Urology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Radiology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Pharmacy Unit, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Pathology, Milan, Italy, Fondazione IRCCS - Istituto Nazionale Dei Tumori, Dept. of Experimental Oncology and Molecular Medicine, Milan, Italy.

Is neoadjuvant chemotherapy beneficial before radical cystectomy? Examining the external validity of the SWOG-8710 trial
By: Hanna N.1, Trinh Q.-D.1, Sammon J.2, Seisen T.1, Vetterlein M.1, Moreira R.1, Preston M.1, Lipsitz S.1, Bellmunt J.3, Menon M.2, Choueiri T.3, Abdollah F.2
Institutes: Brigham and Women’s Hospital, Harvard Medical School, Dept. of Urology, Boston, United States of America, Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America, Henry Ford Hospital, Dept. of Urology, Detroit, United States of America, Dana-Farber Cancer Institute, Dept. of Medical Oncology, Boston, United States of America.

An inconvenient truth: Difference between patient-reported and doctor-reported outcomes in advanced urothelial carcinoma
By: Hamano I.1, Hatakeyama S.1, Narita T.1, Fukushima K.1, Yamamoto H.1, Soma O.1, Matsumoto T.1, Tobisawa Y.1, Yoneyama T.2, Imai A.3, Yoneyama T.1, Hashimoto Y.2, Koie T.3, Ohyama C.1
Institutes: Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, Hirosaki University School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan.

Survival benefit of neoadjuvant chemotherapy for muscle invasive bladder cancer in elderly patients
By: Hamano I.1, Hatakeyama S.1, Oikawa M.1, Narita T.1, Hagiwara K.1, Tanaka T.1, Noro D.1, Yuki T.1, Yamamoto H.1, Yoneyama T.2, Imai A.1, Yoneyama T.1, Hashimoto Y.2, Koie T.3, Ohyama C.1
Institutes: Hirosaki University School of Medicine, Dept. of Urology, Hirosaki, Japan, Hirosaki University School of Medicine, Dept. of Advanced Transplant and Regenerative Medicine, Hirosaki, Japan.
**Poster Session 13**

178  
The pathological and clinical response of the luminal and basal subtypes of muscle-invasive bladder cancer to neoadjuvant cisplatin-based chemotherapy and radical cystectomy depend on the immunohistochemical classification system  
By: Zhang R.1, Chen H.1, Xia J.2, Shi O.3, Cao M.1, Jin D.1, Li C.4, Zhuang G.5, Liu Q.2, Xue W.1, Radvanyi F.6, Allory Y.7, Huang Y.1  
Institutes: 1Shanghai Renji Hospital, Dept. of Urology, Shanghai, China, 2Shanghai Renji Hospital, Dept. of Pathology, Shanghai, China, 3Shanghai Jiao Tong University School of Medicine, Dept. of Epidemiology and Statistics, Shanghai, China, 4Chinese Academy of Sciences, Chinese Academy of Sciences Protein Science Core Facility Center, Institute of Biophysics, Beijing, China, 5Renji-Med X Clinical Stem Cell Research Center, Renji Hospital, State Key Laboratory of Oncogenes and Related Genes, Shanghai, China, 6Institut Curie, CNRS, UMR 144, Paris, France, 7AP-HP, Hôpitaux Universitaires Henri-Mondor, Dept. of Pathology, Créteil, France

179  
Impact of adjuvant chemotherapy in patients with pT3NanyM0 upper tract urothelial cancer following radical nephroureterectomy  
By: Song W.1, Choi Y.H.1, Chung H.W.1, Lee C.U.1, Na J.P.1, Choi S.M.2, Sung H.H.1, Jeon H.G.1, Jeong B.C.1, Seo S.I.1, Jeon S.S.1, Choi H.Y.1, Lee H.M.1  
Institutes: 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Dept. of Urology, Seoul, South Korea, 2Gyeongsang National University Hospital, Dept. of Urology, Jinju, South Korea

180  
Multimodal bladder preservation technique for muscle invasive bladder cancer: Results from a prospective trial  
Institutes: 1Osaka Medical College, Osaka, Japan, 2Osaka Medical College, Dept. of Urology, Osaka, Japan, 3Osaka Medical College Mishima-Minami Hospital, Dept. of Urology, Osaka, Japan, 4Osaka Medical College, Dept. of Radiology, Osaka, Japan

15:26 - 15:36  
Aspects on perioperative chemotherapy  
C.N. Sternberg, Rome (IT)